Calcium Oxalate Stones in Cystic Fibrosis: The Role of Vitamin C and Antibiotics
In cystic fibrosis patients, calcium oxalate nephrolithiasis results from a combination of enteric hyperoxaluria (due to fat malabsorption), loss of intestinal oxalate-degrading bacteria from chronic antibiotic use, and potential exacerbation by vitamin C supplementation—which should be discontinued immediately.
Primary Mechanisms in CF Patients
1. Enteric Hyperoxaluria from Fat Malabsorption
CF patients with pancreatic insufficiency develop increased intestinal oxalate absorption through a well-established mechanism 1, 2. When unabsorbed fatty acids bind calcium in the gut, less calcium remains available to complex with dietary oxalate. This free oxalate is then absorbed, leading to hyperoxaluria 1. Additionally, recent research demonstrates that loss of the CFTR protein itself impairs intestinal oxalate secretion mediated by the SLC26A6 transporter, further contributing to net oxalate absorption 3.
2. Antibiotic-Induced Loss of Oxalobacter formigenes
The chronic prophylactic antibiotics are a critical contributor. Studies show that 71% of healthy controls harbor Oxalobacter formigenes (an intestinal bacterium that degrades oxalate), but only 16% of CF patients retain this organism 4. Among CF patients colonized with O. formigenes, all had normal urinary oxalate levels, while 53% of those without colonization developed hyperoxaluria—with the most severe cases in younger patients 4. The single CF patient with normal O. formigenes levels was the only one who had not received antibiotics 4.
Specific antibiotics pose particular risk: cotrimoxazole and ceftazidime have been associated with renal proximal tubular damage, leading to phosphate wasting, secondary hyperparathyroidism, increased 1,25-dihydroxyvitamin D3 formation, and absorptive hypercalciuria 5. There was an inverse correlation (r = -0.91) between cumulative antibiotic exposure and tubular phosphate reabsorption 5.
3. Vitamin C Supplementation as an Exacerbating Factor
Vitamin C supplements must be discontinued. Vitamin C is metabolized to oxalate, and supplementation significantly increases urinary oxalate excretion 6. Studies demonstrate that 1-2 grams daily of vitamin C increases urinary oxalate by approximately 60% in calcium stone formers (from 31-34 mg/24h to 48-50 mg/24h) and significantly elevates the calcium oxalate crystallization index 7. Guidelines explicitly recommend avoiding vitamin C supplements in patients with high urinary oxalate 6.
Additional Contributing Factors
CF patients with stones demonstrate a urinary disequilibrium characterized by:
- Hypercalciuria (from antibiotic-induced tubular dysfunction)
- Hyperoxaluria (mechanisms above)
- Hypocitraturia (reduced stone inhibitor) 5
The citrate/calcium ratio is particularly valuable for discriminating CF patients with stones from those without 5.
Management Algorithm
Immediate Actions:
- Discontinue vitamin C supplements 6
- Limit oxalate-rich foods while maintaining normal dietary calcium intake (1,000-1,200 mg/day) 2
- Increase fluid intake to achieve >2.5 L urine output daily 2, 8
Dietary Modifications for CF Patients:
- Consume calcium WITH meals to bind oxalate in the gut 2. CF patients with enteric hyperoxaluria may benefit from higher calcium intakes, potentially including supplements specifically timed with meals 2
- Low-fat diet or MCT replacement to reduce fatty acid-mediated calcium binding 1
- Limit sodium to <2,300 mg/day 2
- Oral calcium supplementation at mealtime 1
Pharmacologic Considerations:
- Cholestyramine may be considered for oxalate binding, though not always successful 1
- Citrate supplementation to correct hypocitraturia and prevent stone formation 1
- Magnesium supplementation may help prevent stone formation 1
- Correct metabolic acidosis if present 1
Antibiotic Stewardship:
While prophylactic antibiotics cannot be discontinued in CF, awareness of their contribution to stone risk is essential. Consider the cumulative nephrotoxic effects when selecting antibiotic regimens, particularly avoiding prolonged courses of cotrimoxazole and ceftazidime when alternatives exist 5.
Critical Pitfall
Do not restrict dietary calcium in CF patients with stones. Despite counterintuitive reasoning, higher dietary calcium (1,000-1,200 mg/day) reduces stone risk by binding intestinal oxalate 2. Calcium restriction would worsen oxalate absorption. However, calcium supplements taken between meals (rather than with food) may increase stone risk 2.